Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 15, 2024 16:15 ET
|
Marker Therapeutics
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who...
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
April 11, 2024 08:05 ET
|
Tevogen Bio Inc
Tevogen’s Chief Scientific Officer explains the company’s oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.
[Latest] Global Pet Cancer Therapeutics Market Size/Share Worth USD 1,162.4 Million by 2033 at a 9.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 08, 2024 13:30 ET
|
Custom Market Insights
Austin, TX, USA, April 08, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Pet Cancer Therapeutics Market Size, Trends and Insights By Therapy...
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
April 03, 2024 07:00 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024,...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
April 01, 2024 16:05 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the “Company”) (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of...
Hemato Oncology Testing Market Anticipated to Surge Amid Technological Innovations and Increased Cancer Prevalence
January 22, 2024 21:23 ET
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Hemato Oncology Testing Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive research on...
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
December 11, 2023 07:00 ET
|
Marker Therapeutics
HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Oncology Based In-Vivo CRO Industry Experiences Surge with Innovative Solutions: Global Market Report 2023 Explores Trends and Growth Factors
December 11, 2023 04:28 ET
|
Research and Markets
Dublin, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The "Oncology Based In-Vivo CRO Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global market for...
Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
December 08, 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...